On September 3, during the 2021 China International Fair for Trade in Services, Bayer—a multinational pharmaceutical company with long-term roots in China—actively participated in this year's Health and Healthcare Services section. The company reached a cooperation agreement with the Beijing Medical Association on a research project for establishing research-oriented ward models in Beijing. Both parties will collaborate to advance the development of research-oriented wards in the city, explore innovative ward models, and support the innovative development of public hospitals.
Bayer and Beijing Medical Association Collaborate on Research Ward Development Model Study
Research wards serve as dedicated clinical research facilities within qualified hospitals, enabling medical staff to conduct clinical trials of drugs and medical devices, observe the clinical application of new biomedical technologies, and perform other clinical studies. They represent vital medical resources and scientific infrastructure.This research project will examine public hospitals that have already established research-oriented wards. It will analyze the current implementation status, summarize best practices from pilot hospitals, and further explore innovative models for developing research-oriented wards.
Feng Guosheng, President of the Beijing Medical Association, stated: "Advancements in healthcare depend on medical scientific research. Guided by the Beijing Municipal Health Commission and the Beijing Municipal Science and Technology Commission, this project will support hospitals in enhancing clinical research quality, strengthening their research and innovation capabilities, and promoting the development of research wards. This collaboration between the Beijing Medical Association and Bayer represents an effective attempt by academic institutions and enterprises to jointly drive innovation in clinical research."
This year marks the inaugural inclusion of health and medical services as a thematic segment at the China International Fair for Trade in Services (CIFTIS). Amidst significant global public health challenges, healthcare-related topics have garnered heightened attention. At this CIFTIS, Bayer remains committed to its mission of "Science for a Better Life," focusing on diabetes, cardiovascular diseases, and oncology to continuously deliver more and better medicines and treatment options for patients.
Bayer Pharmaceuticals at the 2021 China International Fair for Trade in Services Healthcare Services Special Exhibition
"The CIFTIS serves as a vital window for China's opening-up, offering multinational corporations like Bayer an international platform for showcasing, exchanging, and collaborating. It also provides a crucial avenue for gaining deeper insights into China's local healthcare needs,"" said Zhou Xiaolan, Global Executive Vice President of Bayer's Prescription Medicines Division and President of Bayer China. "Bayer aims to leverage this opportunity to deepen communication and collaboration with Chinese partners, better leverage our expertise in healthcare, continuously deliver more innovative outcomes to the Chinese people, and contribute further to advancing key national strategies like Healthy China."
For over two decades, Bayer Pharmaceuticals has been based in Beijing, consistently providing high-quality innovative medicines to Chinese patients, continuously meeting local healthcare needs, and helping to improve public health. Moving forward, Bayer will continue to leverage its expertise, advance innovation and collaboration, accelerate the delivery of more high-quality and innovative products that meet the health needs of the Chinese people, and help Chinese society achieve a healthier and more prosperous life.